Nasdaq · Biotech stocks database
SANA (Sana Biotechnology Inc.) stock: $2.37, $709.5M market cap, $121.7M cash, $587.8M EV, $801.9M fully diluted market cap. Lead program: SC291 (Non Hodgkin Lymphoma), Phase 1. Data from Fully Diluted's biotech stocks database.
We were founded on the belief that engineered cells will be one of the most important transformations in medicine over the next several decades. The burden of diseases that can be addressed at their root cause through engineered cells is significant. We view engineered cells as having the potential to be as therapeutically disruptive as biologic drugs to clinical practice, enabling us to repair cells in the body when possible and replace them when needed.
Source: 10-K FY2025 via SEC EDGAR
| Cash | $121.7M |
|---|---|
| Debt | $0.0M |
| Net cash | $121.7M |
| Enterprise value | $587.8M |
| Basic shares | 299.6M shares |
| Fully diluted shares | 338.3M shares |
| Fully diluted market cap | $801.9M |
| Cash per share | $0.41 |
| Quarterly burn | $32.8M |
| Cash runway | 4.9 quarters |
Cash figures as of 2026-09-30. Database snapshot: 2026-11-07.
Cap table as of 2026-06-30.
Loading SANA daily closes…